Loading...
Loading...
NERV| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 4.4M |
| Operating I/L | -4.4M |
| Other Income/Expense | 26.9M |
| Interest Income | 0.3M |
| Pretax | 22.5M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 22.5M |
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of product candidates for central nervous system diseases. Its primary focus is on roluperidone, a treatment for schizophrenia, and MIN-301, a neuregulin-1b1 protein for Parkinson's disease and other neurodegenerative disorders.
